GlassScriptPhysician profile
Jeffery T Choh
NPI 1588641104
$7,192.02
in general payments reported to CMS, 2019-2025
34 companies · $84.14 in 2025
The $84.14 reported for 2025 was less than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $49.57 · 2021: $39.26 · 2022: $5,225 · 2023: $671 · 2024: $925 · 2025: $84.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,679.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Trisalus Life Sciences, INC. | $5,228.63 | 2022-2024 | Trinav Infusion System |
| Novartis Pharmaceuticals Corporation | $335.78 | 2019-2025 | |
| Inari Medical, INC. | $209.48 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Telix Pharmaceuticals | $175.72 | 2022-2023 | Illuccix |
| Lilly USA, LLC | $159.53 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Siemens Medical Solutions USA, INC. | $144.07 | 2022-2024 | Magnetom Sola, Biograph Vision 600 (8 Ring/64 Ct), Biograph Mct X-4r |
| Merck Sharp & Dohme LLC | $98.03 | 2019-2024 | Keytruda, Welireg |
| Astellas Pharma US INC | $71.30 | 2023-2024 | Xtandi |
| Springworks Therapeutics, INC. | $68.67 | 2024 | Ogsiveo |
| Pfizer INC. | $61.55 | 2021-2024 | |
| Stryker Corporation | $54.55 | 2022 | |
| Eisai INC. | $46.34 | 2024 | |
| Daiichi Sankyo INC. | $46.33 | 2020-2023 | Injectafer |
| Sirtex Medical INC | $46.19 | 2019-2023 | Sir-Spheres Microspheres |
| Canon Medical Systems USA, INC. | $46.00 | 2022-2024 | Diagnostic Ultrasound System, General Device(S) |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $35.69 | 2024 | Rybrevant |
| Ge Healthcare | $33.82 | 2025 | |
| Histosonics, INC. | $28.82 | 2025 | |
| Progenics Pharmaceuticals, INC. | $28.25 | 2024 | |
| Glaxosmithkline, LLC. | $26.90 | 2024 | Jemperli, Zejula |
| Terumo Medical Corporation | $26.05 | 2019-2020 | |
| Blueprint Medicines Corporation | $22.36 | 2024 | |
| Carl Zeiss Meditec, INC. | $20.22 | 2019 | |
| Leica Microsystems INC. | $19.80 | 2020 | |
| Elucent Medical | $19.52 | 2023 | |
| Cardinal Health 414 LLC | $18.53 | 2022 | |
| Relievant Medsystems, INC. | $18.07 | 2019 | |
| Bard Peripheral Vascular, INC. | $18.06 | 2019 | |
| Merge Healthcare Incorporated | $17.87 | 2022 | |
| Medtronic, INC. | $15.59 | 2024 | Osteocool Rf Ablation System |
| Janssen Pharmaceuticals, INC | $13.67 | 2019 | |
| Merit Medical Systems INC | $12.36 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $12.30 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Choh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.